SCD

Oxbryta Gets Marketing Authorisation In The UK For Patients With Sickle Cell Disease
Κλινικά Νέα

Oxbryta Gets Marketing Authorisation In The UK For Patients With Sickle Cell Disease

Voxelotor, an oral treatment taken once daily, is the first medicine authorized in Great Britain that directly inhibits sickle haemoglobin (HbS) polymerization, the molecular basis of sickling and destruction of…
What’s New In Clinical Trials For Thalassaemia/Sickle Cell Disease Drugs And Therapies?
Κλινικά Νέα

What’s New In Clinical Trials For Thalassaemia/Sickle Cell Disease Drugs And Therapies?

Many pharmaceutical companies are making remarkable progress in their research into candidate treatments for these diseases and 2022 is expected to be yet another eventful year for haemoglobin disorders! Check…
SCD Drug Oxbryta Receives CHMP Positive Opinion For Approval In The EU
Κλινικά Νέα

SCD Drug Oxbryta Receives CHMP Positive Opinion For Approval In The EU

The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion recommending marketing authorization for Oxbryta® (voxelotor) tablets for the treatment of hemolytic…
TIF Releases New Scientific Bulletin To Highlight Research On Haemoglobin Disorders
Κλινικά Νέα

TIF Releases New Scientific Bulletin To Highlight Research On Haemoglobin Disorders

A key objective of the Thalassaemia International Federation is to inform and update regularly the global haemoglobinopathies family, both patients and physicians, on the progress and new developments that arise…
UK & Wales: NICE Recommends First Treatment In Two Decades For Sickle Cell Disease
Κλινικά Νέα

UK & Wales: NICE Recommends First Treatment In Two Decades For Sickle Cell Disease

For the first time in 20 years, a new therapy for sickle cell disease is to be made available on the UK National Health Service (NHS). Crizanlizumab (Adakveo) by Novartis…
Global Blood Submits US Application For Expanded Use Of SCD Drug, Oxbryta, In Patients Aged 4-11 Years
Κλινικά Νέα

Global Blood Submits US Application For Expanded Use Of SCD Drug, Oxbryta, In Patients Aged 4-11 Years

Children with sickle cell disease (SCD) as young as age 4 could be prescribed Oxbryta (Voxelotor) if the U.S. Food and Drug Administration (FDA) approves a supplemental new drug application (sNDA) submitted by…
Adakveo (crizanlizumab)
Clinical Trial Updates (SCD)

Adakveo (crizanlizumab)

Update: 30 June 2022 No update available.   Update: 25 April 2022 Adakveo (crizanlizumab) is now available on the U.K.’s National Health Service (NHS) for sickle cell disease (SCD) patients…
Oxbryta (voxelotor)
Clinical Trial Updates (SCD)

Oxbryta (voxelotor)

Update: 30 June 2022 Presented at EHA2022: Data from the Retrospective Study to Evaluate Outcomes in Patients with Sickle Cell Disease Treated with Oxbryta (RETRO), the first multicenter, retrospective study to examine the real-world…
Clinical Trials Update: The June 2021 Edition
Κλινικά Νέα

Clinical Trials Update: The June 2021 Edition

TIF provides you with comprehensive and up-to-date information on developing drugs and therapies for thalassaemia and sickle cell disease (SCD) currently in clinical trials. Our most recent June 2021 update…
TIF Is Actively Participating In The 26th EHA Annual Congress
Κλινικά Νέα

TIF Is Actively Participating In The 26th EHA Annual Congress

TIF is excited to be participating in the 26th EHA Annual Congress, held this year virtually on 09 – 17 June 2021. Ms Lily Cannon, TIF Operations Manager, attended a…
Back to top button